Q2 2024 Highlights and FY 2024 Outlook
- Revenue of $312.3 million increased 20% compared to revenue of $259.6 million
- Clinician base increased 14% to 6,984 clinicians, a sequential net increase of 118 in the second quarter
- Second quarter visit volumes increased 15% to 2.0 million
- Net loss of $23.3 million, primarily driven by stock-based compensation, compared to net loss of $45.5 million
- Adjusted EBITDA of positive $28.6 million compared to Adjusted EBITDA of positive $14.1 million
- For full year 2024, raising revenue expectations to $1.2 billion to $1.242 billion; raising Center Margin expectations to $363 million to $383 million; raising Adjusted EBITDA expectations to $90 million to $100 million; and reiterating expectations for positive Free Cash Flow
Conference Call, Webcast Information, and Presentations
LifeStance will hold a conference call today, August 8, 2024 at 8:30 a.m. Eastern Time to discuss the second quarter 2024 results. Investors who wish to participate in the call should dial 1-800-715-9871, domestically, or 1-646-307-1963, internationally, approximately 10 minutes before the call begins and provide conference ID number 1488997 or ask to be joined into the LifeStance call. A real-time audio webcast can be accessed via the Events and Presentations section of the LifeStance Investor Relations website (https://investor.lifestance.com), where related materials will be posted prior to the conference call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.